Antitumor mechanisms when pRb and p53 are genetically inactivated

Liang Zhu, Z. Lu, H. Zhao

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.

Original languageEnglish (US)
Pages (from-to)4547-4557
Number of pages11
Issue number35
StatePublished - Aug 27 2015

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Antitumor mechanisms when pRb and p53 are genetically inactivated'. Together they form a unique fingerprint.

Cite this